• Product Name:Adagrasib
  • Molecular Formula:C32H35ClFN7O2
  • Purity:99%
  • Molecular Weight:604.1

Product Details:

CasNo: 2326521-71-3

Molecular Formula: C32H35ClFN7O2

Chinese Manufacturer Supply Adagrasib,Hot Sale 2326521-71-3 Cheap Price

  • Molecular Formula:C32H35ClFN7O2
  • Molecular Weight:604.1
  • Melting Point:From > 262 mg/mL to < 0.010 mg/mL 

Adagrasib(Cas 2326521-71-3) Usage


Adagrasib, marketed under the brand name Krazati, is an oral medication developed by Mirati Therapeutics and used as an anticancer treatment for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). As an enzyme inhibitor belonging to the class of KRAS inhibitors, Adagrasib targets the RAS GTPase family.


This medication is prescribed for adults who have undergone at least one prior treatment and have NSCLC that has either spread to nearby tissues or other parts of the body or cannot be surgically removed. Adagrasib works by disrupting the growth of cancer cells, leading to their eventual destruction.

2326521-71-3 Relevant articles

KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRASG12C mutation from a phase 1/2 study

Pasi A. Jänne1; Igor I. Rybkin2; Alexander Spira3; Gregory J. Riely4; Kyriakos P. Papadopoulos5; Joshua Sabari6; Melissa L. Johnson7; Rebecca S. Heist8; Lyudmila Bazhenova9, Minal Barve10, Jose M. Pacheco11; Ticiana A. Leal12; Karen Velastegui13; Cornelius Cilliers13; Peter Olson13; James G. Christensen13; Thian Kheoh13; Richard C. Chao13; Sai-Hong Ignatius Ou14

32nd EORTC-NCI-AACR Symposium, October 24-25, 2020

Previously reported data from Phase 1 demonstrated clinical activity with adagrasib (MRTX849) in patients with pretreated KRASG12C NSCLC and CRC • 600 mg BID was chosen as …

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P.A. Jänne I.I. Rybkin A.I. Spira T. Kheoh R.C. Chao S.H.I. Ou


Adagrasib, an investigational agent, is a potent, covalent inhibitor of KRAS G12C that irreversibly and selectively binds to and locks KRAS G12C in its inactive state. Adagrasib was optimized to exhibit a long half-life in order to achieve durable and continuous KRAS inhibition, which is postulated to prevent feedback loops and lead to deep and durable antitumor activity.

Relevant Products